IP Library Granted Patent US 8,119,694
Granted Patent B2
US 8,119,694 · App. 12/542,365 · Granted Feb 21, 2012

High concentration local anesthetic formulations

Assignee: Arcion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,694
App. No.
12/542,365
Granted
Feb 21, 2012
Kind
B2
Abstract

A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.

Claims (27)

1. A method of treating pain comprising topically administering an effective amount of a formulation for treating pain to a site in need thereof,

wherein the formulation comprises a local anesthetic in a gel,

wherein the local anesthetic is present in the gel in an amount from 40% by weight up to 60% by weight of the formulation,

wherein the local anesthetic comprises a free base caine alkaloid, and an effective amount of the free base caine alkaloid local anesthetic is released into the skin to provide pain relief at or near the site of administration without systemic toxicity for at least three hours.

2. The method of claim 1 wherein the local anesthetic is selected from the group consisting of dibucaine, bupivacaine, etidocaine, tetracaine, lidocaine, and xylocalne.

3. The method of claim 2 wherein the local anesthetic is lidocaine.

4. The method of claim 1 wherein the local anesthetic is present in an amount of approximately 40% by weight.

5. The method of claim 1 providing an initial burst release within two hours of administration.

6. The method of claim 1 providing an initial burst release within four hours of administration.

7. The method of claim 1 providing an initial burst release within six hours of administration.

8. The method of claim 1 providing an initial burst release within eight hours of administration.

9. The method of claim 1 providing an initial burst release within twelve hours of administration.

10. The method of claim 1 wherein the concentration of the local anesthetic is sufficiently high that release is not governed by simple diffusion.

11. The method of claim 1 wherein the formulation is administered to wounds, abrasions, or burns.

12. The method of claim 1 wherein the formulation is administered to a site prior to a needle insertion or other medical procedure.

13. The method of claim 1 wherein the formulation is administered to a site prior to a cosmetic procedure.

14. The method of claim 13 wherein the cosmetic procedure is removal of hair.

15. The method of claim 1 wherein the formulation is administered to a child.

16. The method of claim 1 wherein the formulation is administered to an animal.

17. The method of claim 1 wherein the formulation comprises one or more excipients selected from the group consisting of isopropyl myristate, a permeation enhancer, propylene glycol, dimethyl isosorbide, ethanol, hydroxypropyl cellulose, hydroxyethyl cellulose, benzyl alcohol and sorbitol.

18. The method of claim 17 , wherein the permeation enhancer is diethyleneglycol monoethyl ether.

19. The method of claim 18 , wherein the formulation comprises diethyleneglycol monoethyl ether, propylene glycol, ethanol, and hydroxypropyl cellulose.

20. The method of claim 19 , wherein the formulation further comprises isopropyl myristate or dimethyl isosorbide.

21. The method of claim 17 , wherein the local anesthetic is present in an amount of about 40% by weight.

22. The method of claim 20 , wherein the local anesthetic is present in an amount of about 40% by weight.

23. The method of claim 21 , wherein the formulation comprises about 40% by weight lidocaine free base, about 10% by weight diethyleneglycol monoethyl ether, about 10% by weight propylene glycol, about 10% by weight dimethyl isosorbide, about 10% by weight ethyl acetate, about 18.8% by weight isopropyl alcohol, and about 1.2% by weight hydroxypropyl cellulose.

24. The method of claim 22 , wherein the formulation comprises about 40% by weight lidocaine free base, about 10% by weight diethyleneglycol monoethyl ether, about 20% by weight propylene glycol, about 18.8% by weight ethanol, and about 1.2% by weight hydroxypropyl cellulose.

Assignments (8)
SECURITY INTEREST Recorded Nov 21, 2025
From: CENTREXION THERAPEUTICS CORPORATION
To: ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 073683/0108 →
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 073683/0099 →
SECURITY INTEREST Recorded Jul 12, 2023
From: CENTREXION THERAPEUTICS CORPORATION
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 064256/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: CENTREXION I, INC.
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 036383/0788 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 032506 FRAME: 0570. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Nov 5, 2014
From: VALLINEX, INC.
To: CENTREXION I, INC.
Reel/Frame 034173/0595 →
MERGER Recorded Mar 24, 2014
From: VALLINEX, INC.
To: CENTREXION I, INC., C/O CENTREXION CORPORATION
Reel/Frame 032506/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2014
From: ARCION THERAPEUTICS, INC.
To: VALLINEX, INC.
Reel/Frame 032506/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2009
From: CAMPBELL, JAMES N.; MICHAELIS, ARTHUR F.
To: ARCION THERAPEUTICS, INC.
Reel/Frame 023458/0231 →
Continuity (2)
Provisional Application 61089348 · Aug 15, 2008
Related Publication 20100041765A1 · Feb 18, 2010